Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Gains from Sales and Divestitures (2019 - 2024)

Historic Gains from Sales and Divestitures for Assembly Biosciences (ASMB) over the last 6 years, with Q4 2024 value amounting to $51872.0.

  • Assembly Biosciences' Gains from Sales and Divestitures rose 2091.94% to $51872.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $51872.0, marking a year-over-year increase of 2091.94%. This contributed to the annual value of $51872.0 for FY2024, which is 2091.94% up from last year.
  • Assembly Biosciences' Gains from Sales and Divestitures amounted to $51872.0 in Q4 2024, which was up 2091.94% from $42898.0 recorded in Q4 2023.
  • In the past 5 years, Assembly Biosciences' Gains from Sales and Divestitures registered a high of $347096.0 during Q4 2021, and its lowest value of $42898.0 during Q4 2023.
  • In the last 5 years, Assembly Biosciences' Gains from Sales and Divestitures had a median value of $143491.5 in 2021 and averaged $164834.6.
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first skyrocketed by 13538.88% in 2020, then plummeted by 8279.79% in 2023.
  • Assembly Biosciences' Gains from Sales and Divestitures (Quarter) stood at $297133.0 in 2020, then increased by 16.82% to $347096.0 in 2021, then dropped by 28.15% to $249376.0 in 2022, then plummeted by 82.8% to $42898.0 in 2023, then grew by 20.92% to $51872.0 in 2024.
  • Its Gains from Sales and Divestitures was $51872.0 in Q4 2024, compared to $42898.0 in Q4 2023 and $249376.0 in Q4 2022.